Facebook
Twitter
LinkedIn
Forward
In June of 2023 the AASLD updated the nomenclature for NAFLD to Metabolic dysfunction-Associated Steatotic Liver Disease(MASLD).
|
Obesity is a chronic, serious life threatening disease, but treatments exist. Obesity is associated with an increased risk of CVD and CV-associated mortality.
|
Sarcopenic obesity presents numerous risks to health and quality of life.
|
Review some common definitions of metabolic syndrome and its relationship to the underlying driving force behind its development, insulin resistance.
|
Explore the direct and indirect connections between obesity and heart disease, as well as practical strategies for managing heart disease through obesity treatment.
|
Obesity is emerging as a serious and complex health condition affecting about 1 billion people in the world.
|
Obesity and bariatric surgery are a risk factor for kidney stones and chronic kidney disease.
|
This session will focus on the management of non-alcoholic fatty liver disease (NAFLD) with a particular emphasis on the role of GLP-1 agonists and SGLT-2 inhibitors in treating this condition.
|
The gut microbiome is recognized as an important factor in obesity. This webinar will review the interconnection between obesity and the gut microbiome.
|
A case definition of lipedema is an important, practical step forward in identifying how lipedema is diagnosed and distinct from usual obesity. Join us for this upcoming webinar where we will desc
|